FDA continues to take Root Cause Analysis and CAPA very seriously

An FDA Warning Letter was issued to a company in California (USA). Once again-similar to several Warning Letters issued in recent weeks-the phrase "you failed to identify the root cause(s), implement appropriate corrective action and preventive action (CAPA), and expand the investigation to evaluate the impact on other batches or products" is not filler. It is a precise, technical finding indicating that the firm's investigation system is not effectively controlling risk.

When this phrase appears, the FDA is signalling significant deficiencies in root cause analysis, CAPA design, CAPA effectiveness, and Quality Unit (QU) oversight, often extending across multiple products and systems, not just a single batch.

What Triggered the Finding

• The Quality Unit (QU) did not investigate an out-of-specification (OOS) identification test result for an incoming lot of active pharmaceutical ingredient (API).
• The QU failed to adequately investigate multiple microbial OOS results from the water system.
• The QU failed to adequately investigate multiple OOS stability failures (pH and viscosity) for a released batch.

According to the FDA, the completed investigations referenced in the firm's response "were not sufficiently thorough and lack sufficient scientific justification to support the identified root cause" (e.g., attributing the issue to "sampling error by the technician" or or rejected due to a lack of OOS results in the final product). Furthermore, the firm failed "to provide supporting documentation or sufficient details about the CAPAs to ensure they will be effective in resolving the deficiency", and did not conduct "a retrospective review of all manufacturing and laboratory investigations."

In another deviation concerning microbiological test methods where a laboratory technician reportedly collected samples primarily "by memory", the firm stated that the investigation was "underway" and, due to "resource issues," would be addressed only after implementation of a related CAPA.

FDA's Conclusion

The FDA recommended that the firm engage a CGMP consultant to "evaluate operations and to assist in meeting CGMP requirements," emphasizing systemic weaknesses within the company's quality systems. The agency further reminded the firm that executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.